Concepts (264)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Aging | 31 | 2023 | 1491 | 3.130 |
Why?
|
| Alzheimer Disease | 33 | 2024 | 2028 | 3.100 |
Why?
|
| Cognitive Dysfunction | 17 | 2024 | 989 | 2.200 |
Why?
|
| Hospitalization | 5 | 2019 | 290 | 1.730 |
Why?
|
| Cognition | 21 | 2024 | 1276 | 1.630 |
Why?
|
| Dementia | 11 | 2024 | 521 | 1.600 |
Why?
|
| Aged, 80 and over | 55 | 2024 | 4594 | 1.590 |
Why?
|
| Health Literacy | 7 | 2018 | 104 | 1.460 |
Why?
|
| Independent Living | 12 | 2022 | 298 | 1.320 |
Why?
|
| Aged | 59 | 2024 | 8595 | 1.280 |
Why?
|
| Female | 62 | 2024 | 14520 | 1.120 |
Why?
|
| Male | 62 | 2024 | 14168 | 1.080 |
Why?
|
| Activities of Daily Living | 10 | 2022 | 571 | 1.040 |
Why?
|
| Cohort Studies | 20 | 2024 | 1801 | 0.930 |
Why?
|
| Humans | 76 | 2024 | 26260 | 0.930 |
Why?
|
| Decision Making | 12 | 2016 | 211 | 0.880 |
Why?
|
| Brain | 15 | 2024 | 1603 | 0.870 |
Why?
|
| Economics | 3 | 2018 | 17 | 0.830 |
Why?
|
| Longitudinal Studies | 17 | 2023 | 1295 | 0.750 |
Why?
|
| DNA-Binding Proteins | 5 | 2022 | 262 | 0.740 |
Why?
|
| Social Behavior | 2 | 2011 | 62 | 0.720 |
Why?
|
| Work | 1 | 2020 | 6 | 0.720 |
Why?
|
| Women | 1 | 2020 | 13 | 0.710 |
Why?
|
| TDP-43 Proteinopathies | 2 | 2021 | 102 | 0.640 |
Why?
|
| National Institute on Aging (U.S.) | 1 | 2019 | 17 | 0.630 |
Why?
|
| Emergencies | 1 | 2019 | 34 | 0.620 |
Why?
|
| Cognition Disorders | 5 | 2016 | 970 | 0.560 |
Why?
|
| Social Participation | 2 | 2022 | 12 | 0.560 |
Why?
|
| Interpersonal Relations | 3 | 2014 | 96 | 0.560 |
Why?
|
| Neuropsychological Tests | 15 | 2021 | 1192 | 0.550 |
Why?
|
| Biomarkers | 2 | 2020 | 556 | 0.550 |
Why?
|
| Information Literacy | 2 | 2014 | 9 | 0.540 |
Why?
|
| Risk Assessment | 1 | 2019 | 592 | 0.530 |
Why?
|
| United States | 9 | 2024 | 2043 | 0.510 |
Why?
|
| Motor Activity | 3 | 2013 | 311 | 0.500 |
Why?
|
| Caregivers | 10 | 2008 | 119 | 0.470 |
Why?
|
| Delay Discounting | 1 | 2015 | 24 | 0.470 |
Why?
|
| Risk Reduction Behavior | 1 | 2015 | 45 | 0.470 |
Why?
|
| Social Environment | 2 | 2011 | 76 | 0.450 |
Why?
|
| Trust | 1 | 2014 | 12 | 0.440 |
Why?
|
| Fraud | 1 | 2014 | 21 | 0.440 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2020 | 170 | 0.420 |
Why?
|
| Mental Health | 2 | 2014 | 113 | 0.420 |
Why?
|
| Age Factors | 8 | 2020 | 744 | 0.410 |
Why?
|
| Medicare | 4 | 2024 | 113 | 0.400 |
Why?
|
| Educational Status | 6 | 2020 | 283 | 0.390 |
Why?
|
| Association | 1 | 2011 | 7 | 0.380 |
Why?
|
| Lewy Body Disease | 1 | 2012 | 95 | 0.370 |
Why?
|
| Mobility Limitation | 2 | 2012 | 90 | 0.370 |
Why?
|
| Cerebral Infarction | 1 | 2012 | 148 | 0.360 |
Why?
|
| Diet, Mediterranean | 2 | 2023 | 95 | 0.350 |
Why?
|
| Risk Factors | 10 | 2022 | 2221 | 0.350 |
Why?
|
| Risk | 4 | 2015 | 197 | 0.340 |
Why?
|
| Loneliness | 3 | 2023 | 59 | 0.310 |
Why?
|
| Follow-Up Studies | 8 | 2019 | 1722 | 0.300 |
Why?
|
| Middle Aged | 18 | 2019 | 8541 | 0.300 |
Why?
|
| Residence Characteristics | 5 | 2016 | 204 | 0.300 |
Why?
|
| Memory | 6 | 2018 | 292 | 0.300 |
Why?
|
| Prospective Studies | 6 | 2019 | 1665 | 0.290 |
Why?
|
| Apolipoprotein E4 | 4 | 2022 | 244 | 0.290 |
Why?
|
| Sex Factors | 7 | 2020 | 456 | 0.280 |
Why?
|
| Autopsy | 5 | 2021 | 328 | 0.280 |
Why?
|
| Brain Infarction | 2 | 2018 | 71 | 0.270 |
Why?
|
| Quality of Life | 3 | 2012 | 606 | 0.260 |
Why?
|
| Proportional Hazards Models | 4 | 2016 | 321 | 0.250 |
Why?
|
| Mental Competency | 4 | 2008 | 10 | 0.250 |
Why?
|
| Social Isolation | 2 | 2023 | 28 | 0.240 |
Why?
|
| Chicago | 7 | 2021 | 857 | 0.240 |
Why?
|
| Mental Status and Dementia Tests | 3 | 2020 | 66 | 0.240 |
Why?
|
| Apolipoproteins E | 3 | 2023 | 241 | 0.230 |
Why?
|
| Genotype | 2 | 2018 | 350 | 0.230 |
Why?
|
| Income | 3 | 2022 | 73 | 0.220 |
Why?
|
| Family | 2 | 2020 | 94 | 0.220 |
Why?
|
| Amyloid beta-Peptides | 5 | 2024 | 320 | 0.210 |
Why?
|
| Neuroimaging | 2 | 2021 | 123 | 0.200 |
Why?
|
| Psychiatric Status Rating Scales | 4 | 2016 | 312 | 0.190 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2022 | 22 | 0.190 |
Why?
|
| Clinical Trials as Topic | 1 | 2002 | 211 | 0.190 |
Why?
|
| Adaptation, Psychological | 1 | 2022 | 154 | 0.190 |
Why?
|
| Disease Progression | 4 | 2020 | 676 | 0.190 |
Why?
|
| Depression | 3 | 2015 | 400 | 0.180 |
Why?
|
| Patient Participation | 4 | 2008 | 49 | 0.180 |
Why?
|
| Politics | 3 | 2008 | 10 | 0.180 |
Why?
|
| Financing, Personal | 3 | 2018 | 20 | 0.180 |
Why?
|
| Social Segregation | 1 | 2020 | 7 | 0.180 |
Why?
|
| Cross-Sectional Studies | 8 | 2022 | 875 | 0.180 |
Why?
|
| Employment | 1 | 2020 | 42 | 0.170 |
Why?
|
| Cognitive Reserve | 1 | 2021 | 38 | 0.170 |
Why?
|
| Personality | 1 | 2021 | 52 | 0.170 |
Why?
|
| Brain Diseases | 1 | 2021 | 60 | 0.170 |
Why?
|
| Socioeconomic Factors | 2 | 2018 | 279 | 0.170 |
Why?
|
| Arteriolosclerosis | 2 | 2021 | 74 | 0.170 |
Why?
|
| Awareness | 1 | 2020 | 44 | 0.160 |
Why?
|
| Cognitive Aging | 1 | 2020 | 73 | 0.160 |
Why?
|
| Memory Disorders | 1 | 2020 | 155 | 0.160 |
Why?
|
| Disability Evaluation | 2 | 2011 | 234 | 0.160 |
Why?
|
| Hospitals, Low-Volume | 1 | 2018 | 6 | 0.150 |
Why?
|
| Hospitals, High-Volume | 1 | 2018 | 7 | 0.150 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2018 | 380 | 0.150 |
Why?
|
| Models, Neurological | 1 | 2018 | 25 | 0.150 |
Why?
|
| Research Subjects | 2 | 2008 | 11 | 0.150 |
Why?
|
| Immunocompromised Host | 1 | 2018 | 43 | 0.150 |
Why?
|
| Mutation | 1 | 2020 | 324 | 0.150 |
Why?
|
| Blood Glucose | 1 | 2018 | 102 | 0.150 |
Why?
|
| Neural Pathways | 1 | 2018 | 65 | 0.150 |
Why?
|
| Nervous System Diseases | 1 | 2019 | 115 | 0.150 |
Why?
|
| Neurofibrillary Tangles | 4 | 2022 | 188 | 0.150 |
Why?
|
| White Matter | 2 | 2016 | 126 | 0.140 |
Why?
|
| Regression Analysis | 2 | 2015 | 249 | 0.140 |
Why?
|
| Hospital Mortality | 1 | 2018 | 130 | 0.140 |
Why?
|
| Prevalence | 2 | 2012 | 441 | 0.140 |
Why?
|
| Exercise | 1 | 2021 | 416 | 0.140 |
Why?
|
| Learning | 2 | 2016 | 65 | 0.140 |
Why?
|
| Stress, Psychological | 2 | 2016 | 218 | 0.140 |
Why?
|
| Ambulatory Care | 1 | 2017 | 66 | 0.140 |
Why?
|
| Cerebrovascular Disorders | 1 | 2018 | 130 | 0.140 |
Why?
|
| Informed Consent | 2 | 2008 | 24 | 0.140 |
Why?
|
| Sepsis | 1 | 2018 | 136 | 0.130 |
Why?
|
| Adult | 6 | 2022 | 7516 | 0.130 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2016 | 12 | 0.130 |
Why?
|
| RNA Splicing | 1 | 2016 | 10 | 0.130 |
Why?
|
| LDL-Receptor Related Proteins | 1 | 2016 | 17 | 0.130 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2018 | 183 | 0.130 |
Why?
|
| Intelligence | 1 | 2016 | 18 | 0.130 |
Why?
|
| Incidence | 3 | 2016 | 709 | 0.130 |
Why?
|
| Gray Matter | 1 | 2016 | 48 | 0.130 |
Why?
|
| Interview, Psychological | 2 | 2008 | 38 | 0.130 |
Why?
|
| Comprehension | 1 | 2016 | 29 | 0.130 |
Why?
|
| Alleles | 2 | 2018 | 206 | 0.120 |
Why?
|
| Chronic Disease | 1 | 2017 | 413 | 0.120 |
Why?
|
| Amyloid | 3 | 2021 | 55 | 0.120 |
Why?
|
| Crime Victims | 1 | 2016 | 33 | 0.120 |
Why?
|
| Health Behavior | 2 | 2014 | 160 | 0.120 |
Why?
|
| Time Factors | 3 | 2014 | 1347 | 0.120 |
Why?
|
| Psychological Tests | 1 | 2015 | 50 | 0.120 |
Why?
|
| Multilingualism | 1 | 2014 | 11 | 0.110 |
Why?
|
| Poverty | 1 | 2015 | 96 | 0.110 |
Why?
|
| Racism | 1 | 2015 | 29 | 0.110 |
Why?
|
| Music | 1 | 2014 | 22 | 0.110 |
Why?
|
| Minority Groups | 1 | 2015 | 78 | 0.110 |
Why?
|
| Neoplasms | 1 | 2017 | 224 | 0.110 |
Why?
|
| tau Proteins | 3 | 2022 | 226 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 160 | 0.110 |
Why?
|
| Social Support | 2 | 2015 | 189 | 0.110 |
Why?
|
| Odds Ratio | 4 | 2018 | 247 | 0.110 |
Why?
|
| Parkinsonian Disorders | 1 | 2016 | 211 | 0.110 |
Why?
|
| Neprilysin | 1 | 2012 | 10 | 0.100 |
Why?
|
| Automobile Driving | 1 | 2012 | 20 | 0.100 |
Why?
|
| Actigraphy | 1 | 2012 | 97 | 0.100 |
Why?
|
| Disabled Persons | 1 | 2013 | 122 | 0.090 |
Why?
|
| Lewy Bodies | 3 | 2018 | 184 | 0.090 |
Why?
|
| Muscle Strength | 1 | 2012 | 134 | 0.090 |
Why?
|
| Health Status | 2 | 2012 | 171 | 0.090 |
Why?
|
| Vascular Diseases | 1 | 2011 | 41 | 0.090 |
Why?
|
| Motor Skills Disorders | 1 | 2010 | 14 | 0.090 |
Why?
|
| Environmental Health | 1 | 2010 | 8 | 0.090 |
Why?
|
| Severity of Illness Index | 2 | 2005 | 853 | 0.090 |
Why?
|
| Phobic Disorders | 1 | 2010 | 65 | 0.090 |
Why?
|
| Urban Population | 1 | 2011 | 144 | 0.080 |
Why?
|
| Surveys and Questionnaires | 2 | 2021 | 1034 | 0.080 |
Why?
|
| Body Mass Index | 1 | 2011 | 432 | 0.080 |
Why?
|
| Third-Party Consent | 1 | 2008 | 1 | 0.070 |
Why?
|
| Ethics, Research | 1 | 2008 | 3 | 0.070 |
Why?
|
| Assisted Living Facilities | 1 | 2008 | 1 | 0.070 |
Why?
|
| Attitude | 1 | 2008 | 32 | 0.070 |
Why?
|
| Nursing Homes | 1 | 2008 | 29 | 0.070 |
Why?
|
| Health Services Needs and Demand | 1 | 2008 | 55 | 0.070 |
Why?
|
| Delivery of Health Care | 2 | 2015 | 147 | 0.070 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2008 | 60 | 0.070 |
Why?
|
| Selegiline | 1 | 2005 | 4 | 0.060 |
Why?
|
| alpha-Tocopherol | 1 | 2005 | 11 | 0.060 |
Why?
|
| Mood Disorders | 1 | 2005 | 28 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2018 | 567 | 0.060 |
Why?
|
| Physician-Patient Relations | 1 | 2005 | 33 | 0.060 |
Why?
|
| Self Report | 2 | 2016 | 197 | 0.060 |
Why?
|
| Civil Rights | 1 | 2004 | 3 | 0.060 |
Why?
|
| Healthy Lifestyle | 1 | 2024 | 37 | 0.050 |
Why?
|
| Illinois | 2 | 2015 | 223 | 0.050 |
Why?
|
| Statistics as Topic | 2 | 2015 | 107 | 0.050 |
Why?
|
| Vitamins | 1 | 2022 | 19 | 0.050 |
Why?
|
| Vitamin D | 1 | 2022 | 36 | 0.050 |
Why?
|
| Unconsciousness | 1 | 2022 | 9 | 0.050 |
Why?
|
| Infarction | 1 | 2022 | 29 | 0.050 |
Why?
|
| Sclerosis | 1 | 2022 | 61 | 0.050 |
Why?
|
| Anthocyanins | 1 | 2022 | 9 | 0.050 |
Why?
|
| Fruit | 1 | 2022 | 25 | 0.050 |
Why?
|
| Logistic Models | 2 | 2018 | 353 | 0.050 |
Why?
|
| Motor Skills | 1 | 2021 | 51 | 0.050 |
Why?
|
| Individuality | 1 | 2021 | 24 | 0.040 |
Why?
|
| Neuroticism | 1 | 2021 | 30 | 0.040 |
Why?
|
| Southeastern United States | 1 | 2020 | 13 | 0.040 |
Why?
|
| Midwestern United States | 1 | 2020 | 59 | 0.040 |
Why?
|
| Religion | 1 | 2019 | 40 | 0.040 |
Why?
|
| Multilevel Analysis | 1 | 2018 | 7 | 0.040 |
Why?
|
| Heterozygote | 1 | 2018 | 96 | 0.040 |
Why?
|
| Neuropathology | 1 | 2018 | 76 | 0.040 |
Why?
|
| Hippocampus | 1 | 2020 | 268 | 0.040 |
Why?
|
| Likelihood Functions | 1 | 2017 | 26 | 0.030 |
Why?
|
| Mental Status Schedule | 2 | 2008 | 88 | 0.030 |
Why?
|
| Length of Stay | 1 | 2018 | 290 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2021 | 1069 | 0.030 |
Why?
|
| Vulnerable Populations | 1 | 2016 | 25 | 0.030 |
Why?
|
| Critical Care | 1 | 2018 | 195 | 0.030 |
Why?
|
| Plaque, Amyloid | 1 | 2017 | 144 | 0.030 |
Why?
|
| Frontal Lobe | 1 | 2016 | 81 | 0.030 |
Why?
|
| Temporal Lobe | 1 | 2016 | 80 | 0.030 |
Why?
|
| Anisotropy | 1 | 2016 | 47 | 0.030 |
Why?
|
| Diagnosis | 1 | 2015 | 23 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2016 | 73 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2016 | 216 | 0.030 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2016 | 84 | 0.030 |
Why?
|
| Epidemiologic Methods | 1 | 2015 | 16 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2016 | 162 | 0.030 |
Why?
|
| Demography | 1 | 2015 | 67 | 0.030 |
Why?
|
| Cities | 1 | 2015 | 16 | 0.030 |
Why?
|
| Financial Management | 1 | 2015 | 23 | 0.030 |
Why?
|
| Life Change Events | 1 | 2014 | 33 | 0.030 |
Why?
|
| Memory, Episodic | 1 | 2016 | 111 | 0.030 |
Why?
|
| Empathy | 1 | 2014 | 38 | 0.030 |
Why?
|
| Mental Recall | 1 | 2014 | 61 | 0.030 |
Why?
|
| Language | 1 | 2014 | 65 | 0.030 |
Why?
|
| Spouses | 2 | 2005 | 23 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 600 | 0.030 |
Why?
|
| Spatial Behavior | 1 | 2012 | 9 | 0.020 |
Why?
|
| Licensure | 1 | 2012 | 9 | 0.020 |
Why?
|
| Accidents, Traffic | 1 | 2012 | 23 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2012 | 22 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 2012 | 14 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2012 | 24 | 0.020 |
Why?
|
| Environment | 1 | 2012 | 45 | 0.020 |
Why?
|
| Transfection | 1 | 2012 | 111 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2012 | 54 | 0.020 |
Why?
|
| Mice | 1 | 2016 | 1380 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2012 | 259 | 0.020 |
Why?
|
| Baltimore | 1 | 2011 | 9 | 0.020 |
Why?
|
| Linear Models | 1 | 2012 | 238 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2012 | 290 | 0.020 |
Why?
|
| Reaction Time | 1 | 2011 | 100 | 0.020 |
Why?
|
| Data Collection | 1 | 2011 | 88 | 0.020 |
Why?
|
| Executive Function | 1 | 2011 | 111 | 0.020 |
Why?
|
| Psychometrics | 1 | 2011 | 232 | 0.020 |
Why?
|
| Psychomotor Performance | 1 | 2011 | 204 | 0.020 |
Why?
|
| Survival Rate | 1 | 2010 | 315 | 0.020 |
Why?
|
| Animals | 1 | 2016 | 3551 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2008 | 108 | 0.020 |
Why?
|
| Observer Variation | 1 | 2008 | 96 | 0.020 |
Why?
|
| Prognosis | 1 | 2010 | 710 | 0.020 |
Why?
|
| Simvastatin | 1 | 2008 | 14 | 0.020 |
Why?
|
| ROC Curve | 1 | 2008 | 133 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2016 | 3285 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 473 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2008 | 303 | 0.020 |
Why?
|
| Professional-Family Relations | 1 | 2005 | 24 | 0.020 |
Why?
|
| Cost of Illness | 1 | 2005 | 41 | 0.020 |
Why?
|
| Judgment | 1 | 2005 | 7 | 0.020 |
Why?
|
| Nootropic Agents | 1 | 2005 | 13 | 0.020 |
Why?
|
| Policy Making | 1 | 2004 | 12 | 0.010 |
Why?
|
| Long-Term Care | 1 | 2004 | 50 | 0.010 |
Why?
|
| Patient Compliance | 1 | 2005 | 148 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2003 | 131 | 0.010 |
Why?
|
| Interviews as Topic | 1 | 2003 | 132 | 0.010 |
Why?
|
| Pennsylvania | 1 | 2002 | 7 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2002 | 90 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2003 | 683 | 0.010 |
Why?
|